SearchAs the Vice President of Immuno-Oncology & Cell and Gene Therapy, Erin Finot is responsible for combining strategic delivery and operational excellence to help sponsors achieve their drug development goals. She and her team provide high quality, nimble, and innovative drug development services, solutions and expertise.
As advancements in immuno-oncology and cell and gene therapies continue to transform patient care, Erin successfully guides sponsors through a dynamic landscape with strong therapeutic expertise and more than 24 years of experience in global clinical research and drug development processes.
Erin’s educational background provides a solid foundation for her domain expertise, including a bachelor’s in biology from the University of California, Berkeley and a master’s degree in immunology from the University of Virginia. She also earned a Master of Business Administration in Finance and Accounting from Louisiana State University, Shreveport.